Finally, let's turn to the New England Journal of Medicine. Speaking of closing the loop, this is the final analysis of overall survival with pembrolizumab in early-stage triple-negative breast cancer ...

Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Aethlon's Hemopurifier® is a clinical stage immunotherapeutic device designed to combat cancer. Read the full article at Investorideas.com According to News-Medical.net, "Immunotherapy, which works ...

Aethlon Medical Granted Full Ethics Approval from the Medanta Institutional Ethics Committee for a Safety, Feasibility, and ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...

Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue Oncology Society ...